Aficamten improves health status, exercise capacity in challenging nonobstructive HCM

MUNICH — In patients with symptomatic nonobstructive hypertrophic cardiomyopathy, aficamten led to greater improvements in health status and exercise capacity at 36 weeks compared with placebo, according to data from the ACACIA-HCM trial.Aficamten (Myqorzo, Cytokinetics) is the first cardiac myosin inhibitor to show benefit in patients with nonobstructive HCM. In December 2025, the FDA

Raccontata dahealio.commedpagetoday.commedicalxpress.com